NDA 020372 · Medi-Physics
Myoview
Technetium Tc-99m Tetrofosmin Kit · Injection
NovelLast checked: Nov 19, 2026Latest source record: Dec 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Feb 9, 1996
Approved uses
3
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
700
170 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 10, 2024.
MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) 1.1 Myocardial Perfusion Imaging Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. 1.2 Ventricular Function Imaging MYOVIEW is indicated for assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.
Mechanism: Technetium (99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium according to myocardial perfusion and viability.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2003 Supplement 13 · Efficacy ReviewLetterLabel
- Nov 23, 2001 Supplement 3 · Efficacy LetterReviewLabel
- Feb 9, 1996 Original approval · Type 1 - New Molecular Entity
2 products under this application
- MYOVIEW · TECHNETIUM TC-99M TETROFOSMIN KIT N/A · INJECTABLE, INJECTION · Prescription
- MYOVIEW 30ML · TECHNETIUM TC-99M TETROFOSMIN KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Tetrofosmin Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event409
- radioisotope scan abnormal274
- drug ineffective152
- product quality issue29
- dizziness21
- headache21
- nausea20
- hypersensitivity16
- scan myocardial perfusion abnormal16
- urticaria16
- vomiting16
- dyspnoea15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 9 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 7 |
| 2012 | 6 |
| 2013 | 8 |
| 2014 | 17 |
| 2015 | 20 |
| 2016 | 35 |
| 2017 | 37 |
| 2018 | 36 |
| 2019 | 83 |
| 2020 | 91 |
| 2021 | 57 |
| 2022 | 38 |
| 2023 | 29 |
| 2024 | 28 |
| 2025 | 59 |
| 2026 | 106 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- IMRT sparing of normal tissues in locoregional treatment of breast cancer.
Caudrelier JM, Meng J, Esche B, et al. · Radiat Oncol 2014 · Clinical Trial, Research Support, Non-U.S. Gov't
- Comparison of left ventricular functional parameters measured by gated single photon emission tomography and by two-dimensional echocardiography.
Singh B, Manoj R, Vikas P, et al. · Hell J Nucl Med 2006 · Controlled Clinical Trial
- Technetium-99m tetrofosmin rest/stress myocardial SPET with a same-day 2-hour protocol: comparison with coronary angiography. A Spanish-Portuguese multicentre clinical trial.
Montz R, Perez-Castejón MJ, Jurado JA, et al. · Eur J Nucl Med 1996 · Clinical Trial, Clinical Trial, Phase III
- Myocardial SPECT: what do we gain from attenuation correction (and when)?
Dondi M, Fagioli G, Salgarello M, et al. · Q J Nucl Med Mol Imaging 2004 · Clinical Trial, Comparative Study
Sponsor: Medi-Physics · Also marketed as Myoview 30ml
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.